Chemiluminescence Immunoassay Market: as high-throughput automated platforms become the default infrastructure for hospital laboratory consolidation, immunoassay menus expand from routine thyroid and fertility panels into cardiac, oncology, and neurodegenerative biomarker categories once exclusive to specialty reference laboratories, so a closed-architecture analyzer’s reagent menu breadth becomes the primary switching cost, and vendors that add the fastest stream of new FDA-cleared assays to an already-installed analyzer base capture disproportionate recurring reagent revenue.

The global chemiluminescence immunoassay market size was USD 23.20 Billion in 2025 and is expected to register a revenue CAGR of 7.2% during the forecast period. Market revenue growth is driven by factors such as hospital laboratory consolidation onto high-throughput automated immunoassay platforms, continuous FDA-cleared reagent menu expansion into cardiac, oncology, and neurodegenerative biomarker categories, and the emergence of blood-based neurological biomarker assays that reduce dependence on more invasive or costly diagnostic procedures. The first driving factor is hospital laboratory consolidation onto a small number of high-throughput, closed-architecture analyzer platforms. Danaher’s Beckman Coulter subsidiary received FDA 510(k) clearance in March 2025 for its DxC 500i integrated clinical chemistry and immunoassay analyzer, offering up to 800 chemistry tests and 100 immunoassay tests per hour on a single consolidated platform. The second driving factor is the continuous expansion of FDA-cleared reagent menus that let an already-installed analyzer capture new testing categories without a new hardware placement. QuidelOrtho received FDA clearance in November 2025 for its VITROS high-sensitivity Troponin I Assay, extending its installed analyzer base into high-sensitivity cardiac biomarker testing. The third driving factor is the emergence of blood-based neurodegenerative biomarker assays that bring specialty neurology testing onto mainstream chemiluminescence platforms. These are some of the key factors driving revenue growth of the market.

A second layer of demand comes from the way a single installed chemiluminescence analyzer widens its own reagent revenue base as new FDA-cleared assays are added to its menu, letting one already-placed instrument capture incremental testing categories without a new capital sale, because the closed-architecture design ties reagent purchasing to the analyzer brand for the equipment’s full service life. Once a hospital laboratory consolidates onto a given analyzer platform, each additional FDA-cleared assay added to that platform’s menu, from a new cardiac biomarker to a new neurodegenerative disease marker, adds recurring reagent revenue without requiring the laboratory to qualify a new instrument, so the value of an installed analyzer compounds as its cleared assay menu grows around it. As a result, demand and revenue share are concentrating around analyzer platforms with the fastest-growing cleared assay menus, and the forecast tilts toward vendors with broad multi-category reagent pipelines rather than single-application specialty immunoassay providers. For instance, in May 2025, Fujirebio, Japan, received FDA clearance for its Lumipulse blood-based p-tau217/Aβ42 ratio test for Alzheimer’s disease, one of a growing menu of neurodegenerative biomarker assays now running on chemiluminescence platforms without requiring specialty neurology laboratory referral. These are some of the key factors driving revenue growth of the market.

The clearest driver of demand is hospital laboratory consolidation onto a small number of high-throughput, closed-architecture analyzer platforms. Consolidation works only if a single platform can cover the breadth of chemistry and immunoassay testing a hospital laboratory previously ran across multiple instruments, and closing that coverage gap is what each new FDA clearance accomplishes, so platform breadth and consolidation momentum reinforce one another. Danaher’s Beckman Coulter subsidiary received FDA 510(k) clearance in March 2025 for its DxC 500i integrated clinical chemistry and immunoassay analyzer, combining up to 800 chemistry tests and 100 immunoassay tests per hour on a single platform designed for laboratories of all sizes. The recent record shows the pace. In February 2026, the FDA cleared chemiluminescent immunoassays from Beckman Coulter for hepatitis B virus antibody detection on the DxI 9000 system and from Siemens Healthineers for thyroid stimulating hormone detection on the Atellica IM instrument in the same clearance cycle. The effect on the market is that hospital systems are increasingly standardising on one or two analyzer platforms rather than maintaining separate instruments for each testing category. These are some of the key factors driving revenue growth of the market.

The second driver is the steady FDA clearance cadence for new chemiluminescence assays that extend an already-installed analyzer’s menu into higher-value specialty categories. Menu expansion works only if a new assay runs on hardware a laboratory has already validated and purchased, and this dependency is precisely what makes each new clearance pure incremental reagent revenue for the analyzer vendor rather than a new competitive sale, so vendors compete on clearance velocity as much as on any single assay’s clinical merit. QuidelOrtho received FDA clearance in November 2025 for its VITROS high-sensitivity Troponin I Assay, extending high-sensitivity cardiac biomarker testing to laboratories already running VITROS systems, with commercial rollout beginning immediately across United States laboratories. Abbott’s Axis-Shield Diagnostics subsidiary received clearance for an NT-proBNP cardiac biomarker assay on the Alinity i platform in the same February 2026 clearance cycle that included Roche’s Cobas Pro Integrated Solution glucose and methadone immunoassay clearances. The effect on the market is that reagent menu breadth, not raw instrument placement count, has become the primary determinant of which vendor captures a given hospital laboratory’s long-run testing revenue. These are some of the key factors driving revenue growth of the market.

“Fujirebio’s May 2025 FDA clearance of its Lumipulse blood-based p-tau217/Aβ42 test brought Alzheimer’s disease biomarker testing onto mainstream chemiluminescence platforms for the first time, ending the historical dependence on cerebrospinal fluid collection for this biomarker class.”

The third driver is the arrival of FDA-cleared blood-based neurodegenerative disease biomarkers that run on standard chemiluminescence platforms rather than requiring cerebrospinal fluid collection or specialty reference laboratory referral. Blood-based neurological testing works only if a chemiluminescence platform can detect biomarker concentrations at the sensitivity that cerebrospinal fluid testing previously required, and clearing that sensitivity bar is what has made blood-based Alzheimer’s testing commercially viable on mainstream analyzers for the first time. Fujirebio received FDA clearance in May 2025 for its Lumipulse blood-based p-tau217/Aβ42 ratio test for Alzheimer’s disease, and Siemens Healthineers has continued expanding its Atellica IM neurological biomarker menu with pTau217 and BDTau blood-based assays, signalling a broader shift toward accessible specimen types in neurology diagnostics. The effect on the market is that neurodegenerative disease testing volume is shifting from a small number of specialty reference laboratories onto the broad installed base of hospital chemiluminescence analyzers. These are some of the key factors driving revenue growth of the market.

However, the chemiluminescence immunoassay market faces severe adoption constraints from matrix interference effects on assay accuracy, the high capital cost of high-throughput analyzer platforms, and closed-architecture reagent lock-in that limits laboratory purchasing flexibility. Because chemiluminescence immunoassay results are vulnerable to haemolysis, icterus, and lipemia present in real-world patient samples, laboratories must maintain rigorous interference-screening protocols and occasionally repeat testing when interference is suspected, adding workflow complexity and turnaround-time cost that grows as reagent menus expand into more analytically sensitive biomarker categories such as high-sensitivity troponin and blood-based neurological markers. Capital cost is a second constraint, because high-throughput analyzer platforms such as Beckman Coulter’s DxC 500i and Siemens’ Atellica systems represent a significant equipment investment that favours large, well-capitalised hospital systems and reference laboratories, so smaller independent laboratories and lower-volume testing sites continue to rely on send-out testing or lower-throughput instruments that cannot support the newest cleared assay menus. Closed-architecture reagent lock-in is the third constraint, since once a laboratory validates and adopts a given analyzer platform, reagent purchasing is effectively locked to that vendor for the equipment’s multi-year service life, reducing laboratories’ negotiating leverage on reagent pricing and creating switching costs that some laboratories view as anti-competitive, so the cost of reagents is not always recovered through improved testing efficiency, and laboratories without strong vendor-negotiation capacity absorb higher per-test costs over an instrument’s lifecycle. These factors substantially limit chemiluminescence immunoassay market growth over the forecast period.

Based on product, the global chemiluminescence immunoassay market is segmented into reagents and kits, analyzers and instruments, software and data management, and consumables. Reagents and kits hold the largest revenue share, because the closed-architecture analyzer business model ties recurring reagent purchasing to each installed instrument for its full multi-year service life, which suits vendors’ strategy of expanding cleared assay menus rather than competing primarily on instrument price. Software and data management remains a smaller, faster-growing category as laboratories digitise result interpretation and connectivity, and it is cheaper to deploy incrementally, but it cannot yet match the revenue scale of the underlying reagent business. Analyzers and instruments are expected to register steady but slower revenue growth in the global chemiluminescence immunoassay market over the forecast period relative to reagents, reflecting the long service life of high-throughput platforms once placed, which is why Danaher and Siemens Healthineers both prioritise menu expansion over frequent hardware refresh cycles.

Based on application, the global chemiluminescence immunoassay market is segmented into infectious disease testing, cardiac biomarker testing, oncology biomarker testing, and endocrinology and hormone testing. Infectious disease testing holds the largest revenue share, reflecting its role as the highest-volume routine testing category across hospital laboratories globally, which suits the high-throughput design of leading chemiluminescence platforms. Cardiac biomarker testing is expected to register rapid revenue growth in the global chemiluminescence immunoassay market over the forecast period, driven by expanding high-sensitivity troponin and NT-proBNP assay clearances from QuidelOrtho and Abbott, which is why cardiac biomarker menu expansion has become a competitive priority for every major analyzer vendor.

Based on end-use, the global chemiluminescence immunoassay market is segmented into hospital laboratories, reference and independent labs, point-of-care settings, and research and academic institutions. Hospital laboratories hold the largest revenue share, because they represent the primary site of high-throughput analyzer consolidation and the largest installed base of closed-architecture chemiluminescence platforms, which suits vendors’ reagent menu expansion strategy. Point-of-care settings are expected to register rapid revenue growth in the global chemiluminescence immunoassay market over the forecast period, driven by lower-throughput analyzer placements bringing chemiluminescence-grade sensitivity closer to the patient, which is why Siemens Healthineers continues expanding its lower-volume Atellica CI analyzer footprint alongside its high-throughput systems.

Based on regional analysis, the chemiluminescence immunoassay market in North America accounted for largest revenue share in 2025. The United States leads because it hosts the largest concentration of hospital laboratory consolidation activity and because Abbott, Danaher, and QuidelOrtho, three of the leading global chemiluminescence immunoassay vendors, concentrate their commercial and FDA clearance activity in the country. QuidelOrtho’s November 2025 VITROS Troponin I clearance and Danaher’s March 2025 DxC 500i clearance both launched first into the United States hospital laboratory market. The concentration of FDA clearance activity in the United States also means new chemiluminescence assay menus are typically cleared and launched in the United States before other regions.

The market in Europe is expected to register a steady revenue growth rate over the forecast period. Germany, the United Kingdom, and France represent the three largest national chemiluminescence immunoassay markets within Europe. Roche and Siemens Healthineers, both headquartered in the region, maintain deep installed bases across European hospital systems, and the EU’s In Vitro Diagnostic Regulation CE-marking pathway moves more deliberately than the FDA’s single-agency clearance process. The result is steady rather than rapid growth, shaped more by the region’s already-mature analyzer installed base than by unmet demand.

The market in Asia Pacific is expected to register a rapid revenue growth rate over the forecast period. China, Japan, and India represent the three largest national chemiluminescence immunoassay markets within the region. Japan is home to Fujirebio, whose Lumipulse neurodegenerative biomarker platform is expanding regionally, while China’s and India’s hospital laboratory modernisation programmes are driving new high-throughput analyzer placements from a comparatively lower installed base, leaving more room for growth than in the already-mature North America and Europe markets.

The market in Latin America is expected to register a moderate revenue growth rate over the forecast period. Brazil and Mexico represent the two largest national chemiluminescence immunoassay markets within the region. Hospital laboratory networks in both countries are expanding high-throughput analyzer capacity, and the indirect effects of Iran-US sanctions and the associated Strait of Hormuz shipping disruption have kept freight and import costs elevated for the specialised chemiluminescence analyzers and reagents that Latin American laboratories depend on through 2026, slowing adoption beyond the region’s main urban hospital systems.

The market in Middle East and Africa is expected to register a moderate revenue growth rate over the forecast period. Saudi Arabia and the UAE represent the primary commercial chemiluminescence immunoassay markets within the GCC. The UAE is the most established chemiluminescence immunoassay market on the continent given its concentrated private hospital infrastructure, while the wider Gulf states and broader African markets are still building high-throughput laboratory testing capacity from scratch.